instruction
stringlengths 22
145
| input
stringclasses 1
value | answer
stringlengths 220
325
| text
stringlengths 382
597
|
|---|---|---|---|
The effect of dosage and administration frequency on the median PFS for CT103A. | The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for CT103A.
### Response:
The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)</sup> |
|
The correlation between the median PFS for CT103A and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for CT103A and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for CT103A. | The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for CT103A.
### Response:
The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)</sup> |
|
The role of supportive care in improving the median PFS for CT103A. | The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for CT103A.
### Response:
The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for CT103A. | The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for CT103A.
### Response:
The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)</sup> |
|
The effect of concurrent health conditions on the median PFS for CT103A. | The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for CT103A.
### Response:
The median progression-free survival (PFS) for the treatment combination of CT103A from FUMANBA-1 was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8025?af=R)</sup> |
|
Median PFS for Belantamab Mafodotin? | The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Belantamab Mafodotin?
### Response:
The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
Comparison of the median PFS for Belantamab Mafodotin with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Belantamab Mafodotin with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The impact of patient characteristics on the median PFS for Belantamab Mafodotin. | The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Belantamab Mafodotin.
### Response:
The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The role of genetic factors in the median PFS for Belantamab Mafodotin. | The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Belantamab Mafodotin.
### Response:
The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The influence of previous treatments on the median PFS for Belantamab Mafodotin. | The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Belantamab Mafodotin.
### Response:
The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Belantamab Mafodotin. | The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Belantamab Mafodotin.
### Response:
The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The correlation between the median PFS for Belantamab Mafodotin and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Belantamab Mafodotin and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Belantamab Mafodotin. | The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Belantamab Mafodotin.
### Response:
The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The role of supportive care in improving the median PFS for Belantamab Mafodotin. | The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Belantamab Mafodotin.
### Response:
The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Belantamab Mafodotin. | The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Belantamab Mafodotin.
### Response:
The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The effect of concurrent health conditions on the median PFS for Belantamab Mafodotin. | The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Belantamab Mafodotin.
### Response:
The median progression-free survival (PFS) for the treatment combination of Belantamab Mafodotin from DREAMM-3 was 11.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
Median PFS for Pomalidomide+Dexamethasone? | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Pomalidomide+Dexamethasone?
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
Comparison of the median PFS for Pomalidomide+Dexamethasone with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Pomalidomide+Dexamethasone with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The impact of patient characteristics on the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The role of genetic factors in the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The influence of previous treatments on the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The correlation between the median PFS for Pomalidomide+Dexamethasone and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Pomalidomide+Dexamethasone and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The role of supportive care in improving the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
The effect of concurrent health conditions on the median PFS for Pomalidomide+Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Pomalidomide+Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone from DREAMM-3 was 7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/)</sup> |
|
Median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd)? | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
Comparison of the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The impact of patient characteristics on the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The role of genetic factors in the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The influence of previous treatments on the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The correlation between the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The role of supportive care in improving the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The effect of concurrent health conditions on the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Carfilzomib+Cyclophosphamide+Dexamethasone (KCd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Cyclophosphamide+Dexamethasone (KCd) from MUK Five was 11.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
Median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd)? | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
Comparison of the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The impact of patient characteristics on the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The role of genetic factors in the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The influence of previous treatments on the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The correlation between the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The role of supportive care in improving the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
The effect of concurrent health conditions on the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd). | The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Cyclophosphamide+Velcade+Dexamethasone (CVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Cyclophosphamide+Velcade+Dexamethasone (CVd) from MUK Five was 10.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.haematologica.org/article/view/haematol.2021.278399)</sup> |
|
Median PFS for Pomalidomide Plus Low-Dose Dexamethasone? | The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Pomalidomide Plus Low-Dose Dexamethasone?
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
Comparison of the median PFS for Pomalidomide Plus Low-Dose Dexamethasone with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Pomalidomide Plus Low-Dose Dexamethasone with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The impact of patient characteristics on the median PFS for Pomalidomide Plus Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Pomalidomide Plus Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The role of genetic factors in the median PFS for Pomalidomide Plus Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Pomalidomide Plus Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The influence of previous treatments on the median PFS for Pomalidomide Plus Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Pomalidomide Plus Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Pomalidomide Plus Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Pomalidomide Plus Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The correlation between the median PFS for Pomalidomide Plus Low-Dose Dexamethasone and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Pomalidomide Plus Low-Dose Dexamethasone and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Pomalidomide Plus Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Pomalidomide Plus Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The role of supportive care in improving the median PFS for Pomalidomide Plus Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Pomalidomide Plus Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Pomalidomide Plus Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Pomalidomide Plus Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The effect of concurrent health conditions on the median PFS for Pomalidomide Plus Low-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Pomalidomide Plus Low-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pomalidomide Plus Low-Dose Dexamethasone from NIMBUS was 4 months with a 95% Confidence Interval (CI) of (3.6, 4.7) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
Median PFS for High-Dose Dexamethasone? | The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for High-Dose Dexamethasone?
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
Comparison of the median PFS for High-Dose Dexamethasone with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for High-Dose Dexamethasone with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The impact of patient characteristics on the median PFS for High-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for High-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The role of genetic factors in the median PFS for High-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for High-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The influence of previous treatments on the median PFS for High-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for High-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The effect of dosage and administration frequency on the median PFS for High-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for High-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The correlation between the median PFS for High-Dose Dexamethasone and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for High-Dose Dexamethasone and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for High-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for High-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The role of supportive care in improving the median PFS for High-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for High-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for High-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for High-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
The effect of concurrent health conditions on the median PFS for High-Dose Dexamethasone. | The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for High-Dose Dexamethasone.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Dexamethasone from NIMBUS was 1.9 months with a 95% Confidence Interval (CI) of (1.9, 2.2) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext)</sup> |
|
Median PFS for Lenalidomide Maintenance? | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Lenalidomide Maintenance?
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
Comparison of the median PFS for Lenalidomide Maintenance with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Lenalidomide Maintenance with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The impact of patient characteristics on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The role of genetic factors in the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The influence of previous treatments on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The correlation between the median PFS for Lenalidomide Maintenance and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Lenalidomide Maintenance and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The role of supportive care in improving the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The effect of concurrent health conditions on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from IFM2005-02 was 41 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
Median PFS for Placebo? | The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Placebo?
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
Comparison of the median PFS for Placebo with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Placebo with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The impact of patient characteristics on the median PFS for Placebo. | The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Placebo.
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The role of genetic factors in the median PFS for Placebo. | The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Placebo.
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The influence of previous treatments on the median PFS for Placebo. | The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Placebo.
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Placebo. | The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Placebo.
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The correlation between the median PFS for Placebo and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Placebo and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Placebo. | The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Placebo.
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The role of supportive care in improving the median PFS for Placebo. | The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Placebo.
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Placebo. | The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Placebo.
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
The effect of concurrent health conditions on the median PFS for Placebo. | The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Placebo.
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo from IFM2005-02 was 23 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1114138)</sup> |
|
Median PFS for G-CSF Plus Plerixafor? | The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for G-CSF Plus Plerixafor?
### Response:
The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)</sup> |
|
Comparison of the median PFS for G-CSF Plus Plerixafor with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for G-CSF Plus Plerixafor with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)</sup> |
|
The impact of patient characteristics on the median PFS for G-CSF Plus Plerixafor. | The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for G-CSF Plus Plerixafor.
### Response:
The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)</sup> |
|
The role of genetic factors in the median PFS for G-CSF Plus Plerixafor. | The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for G-CSF Plus Plerixafor.
### Response:
The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)</sup> |
|
The influence of previous treatments on the median PFS for G-CSF Plus Plerixafor. | The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for G-CSF Plus Plerixafor.
### Response:
The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)</sup> |
|
The effect of dosage and administration frequency on the median PFS for G-CSF Plus Plerixafor. | The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for G-CSF Plus Plerixafor.
### Response:
The median progression-free survival (PFS) for the treatment combination of G-CSF Plus Plerixafor from AMD3100-3102 was 26 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.astctjournal.org/article/S1083-8791(18)30056-9/fulltext)</sup> |
Subsets and Splits